Skip to main content

Mesalazine/sulfasalazine/vedolizumab

Herpes zoster reactivation and treatment failure: case report

    Reactions Weekly volume 1912, page 277 (2022)Cite this article

    This is a preview of subscription content, access via your institution.

    Access options

    Buy single article

    Instant access to the full article PDF.

    USD 49.95

    Price excludes VAT (USA)
    Tax calculation will be finalised during checkout.

    Reference

    • Wu N, et al. Herpes Zoster in a Patient With Ulcerative Colitis After Vedolizumab Initiation-Causal Link or Only Temporal Coincidence?. Inflammatory Bowel Diseases 28: E22-E23, No. 2, Feb 2022. Available from: URL: https://academic.oup.com/ibdjournal/issue

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Mesalazine/sulfasalazine/vedolizumab. Reactions Weekly 1912, 277 (2022). https://doi.org/10.1007/s40278-022-17980-5

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40278-022-17980-5